Axa boosted its stake in shares of Cigna Corporation (NYSE:CI) by 2.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 220,462 shares of the health services provider’s stock after acquiring an additional 5,870 shares during the quarter. Axa owned about 0.09% of Cigna worth $41,213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of CI. Cadence Capital Management LLC grew its stake in shares of Cigna by 0.3% during the second quarter. Cadence Capital Management LLC now owns 9,598 shares of the health services provider’s stock valued at $1,607,000 after buying an additional 33 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Cigna by 2.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,760 shares of the health services provider’s stock worth $295,000 after purchasing an additional 40 shares in the last quarter. Veritable L.P. grew its stake in Cigna by 0.5% in the second quarter. Veritable L.P. now owns 8,220 shares of the health services provider’s stock worth $1,376,000 after purchasing an additional 41 shares in the last quarter. MML Investors Services LLC grew its stake in Cigna by 0.8% in the second quarter. MML Investors Services LLC now owns 5,774 shares of the health services provider’s stock worth $967,000 after purchasing an additional 43 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. grew its stake in Cigna by 2.1% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 2,157 shares of the health services provider’s stock worth $361,000 after purchasing an additional 45 shares in the last quarter. 87.85% of the stock is currently owned by institutional investors.

In other Cigna news, CAO Mary T. Hoeltzel sold 575 shares of the stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $197.03, for a total transaction of $113,292.25. Following the sale, the chief accounting officer now directly owns 2,499 shares of the company’s stock, valued at approximately $492,377.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Alan Muney sold 15,345 shares of the firm’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $200.80, for a total value of $3,081,276.00. Following the sale, the executive vice president now owns 28,457 shares in the company, valued at $5,714,165.60. The disclosure for this sale can be found here. Insiders have sold a total of 34,936 shares of company stock worth $6,979,204 over the last ninety days. 1.30% of the stock is owned by insiders.

Cigna Corporation (NYSE:CI) opened at $204.14 on Friday. The stock has a market capitalization of $50,330.72, a price-to-earnings ratio of 19.67, a P/E/G ratio of 1.56 and a beta of 0.50. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.39 and a quick ratio of 0.39. Cigna Corporation has a 52 week low of $133.11 and a 52 week high of $212.46.

Cigna (NYSE:CI) last announced its quarterly earnings results on Thursday, November 2nd. The health services provider reported $2.83 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.47. The company had revenue of $10.38 billion for the quarter, compared to the consensus estimate of $10.17 billion. Cigna had a return on equity of 18.85% and a net margin of 5.74%. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the firm earned $1.94 EPS. analysts forecast that Cigna Corporation will post 10.34 earnings per share for the current fiscal year.

Several research analysts recently issued reports on the company. Morgan Stanley increased their price objective on Cigna from $195.00 to $223.00 and gave the stock an “overweight” rating in a research note on Friday, November 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $220.00 price objective (up previously from $185.00) on shares of Cigna in a research note on Friday, November 3rd. Jefferies Group increased their price objective on Cigna from $201.00 to $221.00 and gave the stock a “buy” rating in a research note on Friday, October 13th. Credit Suisse Group started coverage on Cigna in a research note on Thursday, November 2nd. They issued an “outperform” rating and a $219.00 price objective on the stock. Finally, Citigroup upped their target price on Cigna from $198.00 to $231.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Cigna currently has a consensus rating of “Buy” and a consensus target price of $201.50.

TRADEMARK VIOLATION NOTICE: “Axa Has $41.21 Million Holdings in Cigna Corporation (CI)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://theolympiareport.com/2017/12/17/axa-has-41-21-million-holdings-in-cigna-corporation-ci.html.

About Cigna

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corporation (NYSE:CI).

Institutional Ownership by Quarter for Cigna (NYSE:CI)

Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with Analyst Ratings Network's FREE daily email newsletter.